Hillo
Hillo is a French AI healthtech company that builds digital twin technology for Type 1 Diabetes management, offering a clinical decision support web app for healthcare providers and a real-time blood glucose prediction API for patient logbook applications, now operating within the Stēto group.
- Company typePrivate
- Founded2016
- HeadquartersPalaiseau, France
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Hillo does
Hillo is a French health technology company that develops an AI-based digital twin platform for precision diabetes care, with a primary focus on Type 1 Diabetes patients using continuous glucose monitoring (CGM) devices. The company operates two products from a single underlying engine: a web application for healthcare providers that performs behavioral pattern analysis, therapeutic habit extraction, and in-silico treatment simulation, and a patient-facing real-time blood glucose prediction capability delivered through an API integrated into third-party logbook applications. The digital twin models are trained on real-world patient datasets from observational trials conducted in France and clinical trials from reference centers in Europe and the US, and the company reports prediction accuracy of 99.9%, 98.6%, and 96.3% within Parkes error grid A+B zones at 30-, 60-, and 90-minute horizons.
The business model is a dual B2B and B2B2C structure: HCP web application access follows an enterprise subscription/recurring licensing motion (evidenced by a "Request a Demo" call-to-action), while the patient prediction engine is monetized through API licensing into partner logbook applications. Target customers are endocrinologists, diabetes specialists, and other HCPs managing complex T1D cases, with end-patients reached indirectly through clinical recommendation or embedded app deployment. The company was co-founded by Stéphane Bidet (CEO) and Nicolas Caleca (CSO), with Pr. Eric Renard (Head of Endocrinology, Lapeyronie University Hospital) serving as clinical advisor since 2017. Hillo has raised approximately $2.37M across seed and early-stage rounds led by NCI Waterstart and has built partnerships with Bpifrance, Microsoft for Startups, NVIDIA Inception, École Polytechnique, HEC Paris, and various French innovation hubs. The company has been acquired by Stēto and now operates within the Stēto group under steto.care.
Hillo firmographics
Firmographics- Name
- Hillo
- Legal name
- Hillo
- Website
- https://hillo.ai
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Hillo is a French AI healthtech company that builds digital twin technology for Type 1 Diabetes management, offering a clinical decision support web app for healthcare providers and a real-time blood glucose prediction API for patient logbook applications, now operating within the Stēto group.
- Ownership category
- akta.pro rank
Hillo industry classification
Industry- Product category
- Diabetes Management Software
- NAICS
- Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)
- akta.pro secondary industries
- Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)
Keywords
Where Hillo is headquartered
LocationHeadquarters
- HQ city
- Palaiseau
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Hillo business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- HCP Web Application Licensing: B2B licensing of the web application platform to healthcare providers (HCPs) for clinical decision support in diabetes management. The platform enables HCPs to analyze patient data, simulate treatment changes, and develop personalized treatment plans.
- Patient API Integration: API-based integration of the prediction engine into patient-facing logbook applications, enabling real-time blood glucose prediction and personalized recommendations for preventive actions.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
Hillo product offering
Product offeringCore offering
Hillo develops an AI-based digital twin platform that builds patient-specific glycemic models from continuous glucose monitoring (CGM), insulin dosing, and meal data. It sells two offerings: (1) a web application for healthcare providers that performs ML-driven glycemic pattern analysis, therapeutic habit extraction, and in-silico treatment simulation to optimize diabetes management plans, and (2) a real-time blood glucose prediction API integrated into patient-facing logbook applications that delivers personalized preventive recommendations to patients.
Product overview
Hillo offers a dual-product portfolio centered on AI-based digital twin technology for precision diabetes care. The core offering consists of: (1) Hillo for HCPs – a web application for healthcare providers that uses ML algorithms to extract behavioral patterns and therapeutic habits, perform glycemic pattern analysis, and generate tailored treatment plans via in-silico simulation; and (2) Hillo for Patients – a real-time blood glucose prediction capability integrated into patient-facing logbook applications through the Hillo API. Both products are powered by a proprietary digital twin engine trained on real-world patient data that simulates glycemic response to insulin dosage and meal timing adjustments.
Differentiator
Problem solved
Functional benefit
Products and services
- Hillo for HCPs (Web Application) Web application for healthcare providers that uses ML to extract behavioral patterns and therapeutic habits, perform glycemic pattern analysis, and generate tailored treatment plans via in-silico digital twin simulation; designed for endocrinologists and diabetes specialists managing Type 1 Diabetes patients on CGM.
- Hillo for Patients (Real-Time Blood Glucose Prediction API) API-based real-time blood glucose prediction capability integrated into patient-facing logbook applications; uses Hillo's digital twin to predict glucose direction and risk of hypo/hyperglycemia and deliver personalized preventive recommendations to Type 1 Diabetes patients using CGM.
Quantifiable outcome
- Prediction accuracy up to 99.9%, 98.6%, and 96.3% of computed blood glucose values within Parkes error grid A+B zones at 30-, 60-, and 90-minute horizons
- +2 more outcomes
Companies that use Hillo
Customer profileSegments2 records
Ideal customer profiles2 records
Hillo technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature6 records
Hillo partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, moderate and minor.
- future4carecoreFuture4care is a partner organization shown in Hillo's partners section. Future4care appears to be a health-tech accelerator or innovation hub based in France.
- AI for HealthcoreAI for Health is listed as a partner. The organization appears to focus on AI applications in healthcare, aligning with Hillo's diabetes management technology.
- Microsoft for StartupscoreHillo participates in Microsoft for Startups program, providing access to Azure cloud infrastructure and Microsoft technology stack integration.
- NVIDIA InceptioncoreHillo is part of NVIDIA's startup program, providing access to GPU computing resources and technical support for AI/ML model development.
- École PolytechniquemoderateÉcole Polytechnique (France's leading engineering school) is listed as a partner, likely providing research collaboration and talent access.
- HEC ParismoderateHEC Paris (leading business school) is listed as a partner, potentially providing business strategy support, talent, and entrepreneurship resources.
- Paris & CominorParis & Co is Paris's agency for business and innovation support, providing incubation and acceleration services.
- AgoranovminorAgoranov is a French startup incubator providing support services to early-stage technology companies.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Hillo competitors and assessment
Company assessmentEmerging players
- Rimidi: Digital health platform offering disease-management software for diabetes and related cardiometabolic conditions, with EHR-integrated decision support. Comparable as a chronic disease management software company with a clinical decision support offering for diabetes providers.
- Glytec: Provider of insulin dosing decision support software (Glucommander) for hospitals and outpatient settings. Comparable as an AI-based clinical decision support company for insulin dosing with enterprise sales to providers, although its primary focus is inpatient rather than T1D ambulatory care.
- Beta Bionics: Developer of the iLet bionic pancreas, an automated insulin delivery system using algorithmic dosing decisions. Comparable as a competing AI-driven dosing approach in Type 1 diabetes; potential complement or alternative to Hillo's digital twin technology.
Broad incumbents
- Tandem Diabetes Care: Maker of insulin pumps and the t:slim X2 automated insulin delivery system with embedded bolus calculator and prediction algorithms. Comparable as a Type 1 diabetes device-and-software player that combines hardware with clinical decision support, and a potential partner or competitor for Hillo's prediction engine.
- Dexcom: Leading CGM device maker expanding into decision-support software, including the Dexcom Clarity analytics platform. Comparable because it owns the upstream CGM data pipeline Hillo depends on and increasingly competes in the HCP analytics and patient prediction layer.
- Insulet: Maker of the Omnipod tubeless insulin pump with embedded bolus calculator and SmartAdjust automated insulin delivery technology. Comparable as a Type 1 diabetes device-plus-software company with embedded dose decision support, serving overlapping endocrinology and patient segments.
Direct peers
- One Drop: Digital health platform combining a CGM-connected app, AI-based glucose prediction, and coaching for diabetes management. Directly comparable as an AI-driven diabetes prediction and self-management product with both consumer and B2B components.
- mySugr (Roche): Diabetes self-management logbook app and decision support platform acquired by Roche, offering CGM data integration, bolus advice, and patient coaching. Directly comparable as a consumer-facing diabetes app with a B2B2C model and HCP-facing tools.
- Glooko: Diabetes data management platform that aggregates CGM, pump, and logbook data and offers HCP-facing analytics and patient-facing apps. Directly comparable as a diabetes data platform with both an HCP clinical dashboard and consumer logbook product, competing for the same workflow.
- Diabeloop: French company developing an AI-based closed-loop insulin delivery system with embedded glucose prediction algorithms for Type 1 diabetes. Highly comparable French/European competitor operating in the same AI-driven diabetes management category with similar clinical evidence positioning.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Hillo social profiles
Digital presenceHillo financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hillo leadership team
Management profileNumber of profiles
Profiles3 records
Hillo funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hillo M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hillo
What does Hillo do?
Hillo develops an AI-based digital twin platform that builds patient-specific glycemic models from continuous glucose monitoring (CGM), insulin dosing, and meal data. It sells two offerings: (1) a web application for healthcare providers that performs ML-driven glycemic pattern analysis, therapeutic habit extraction, and in-silico treatment simulation to optimize diabetes management plans, and (2) a real-time blood glucose prediction API integrated into patient-facing logbook applications that delivers personalized preventive recommendations to patients.
Is Hillo a public or private company?
Hillo is a private company. It is classified as corporate owned and is currently operating.
When was Hillo founded?
Hillo was founded in 2016. It employs 11 to 50 people.
Where is Hillo based?
Hillo is headquartered in Palaiseau, France, in the Europe region.
How does Hillo make money?
Two revenue lines are on record. HCP Web Application Licensing is the primary driver. The others are patient API Integration.
Who are Hillo's main competitors?
Emerging players on record are Rimidi, Glytec and Beta Bionics. Broad incumbents are Tandem Diabetes Care, Dexcom and Insulet. Direct peers are One Drop, mySugr (Roche), Glooko and Diabeloop.
Does Hillo have an API?
Yes. Hillo provides an API for patient-facing integration. The API enables real-time blood glucose prediction, allowing patients to receive personalized recommendations for preventive actions when they don't know the direction of their glucose levels or whether they are at risk of hypo or hyperglycemia. The digital twin technology powers predictions to help patients avoid anticipated glycemic excursions. Integrated into a logbook app through the API.
What industry is Hillo in?
Hillo's product category is Diabetes Management Software. Its primary akta.pro industry code is HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators), with a secondary code of HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity). Its NAICS code is 5132 and its SIC code is 7372.